AgomAb Therapeutics NV [AGMB]
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 15.90% | 15.03% | 2.28% |
| Loss % | -11.40% | -11.40% | 6.39% |
| Duration | 11.2d | 13d | 4.1d |
| Total Pivots Found | 6 |
| Gain/Loss Legs | 5 (3 Gain / 2 Loss) |
| Last Pivot | Top @ $12.00 on 2026-06-03 |
| Change since Last Pivot | $-2.39 (-19.92%) |
Next Pivot Prediction Last: $9.61
| Predicted Next Type | Bottom |
| Predicted Price (Avg) | $10.63 |
| Predicted Price (Median) | $10.63 |
| Predicted Price Range (~68%) | $9.87 - $11.40 |
| Change to Avg Target | $1.02 (10.63%) |
| Predicted Date (Avg) | 2026-06-14 |
| Predicted Date Range (~68%) | 2026-06-10 - 2026-06-18 |
| Basis | Based on 2 historical losses (Avg: -11.40%, Median: -11.40%, StdDev of Abs: 6.39%) and duration (Avg: 11.2 days, StdDev: 4.1 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
AgomAb Therapeutics NV fell moderately, down -2.73% on Friday.
AgomAb Therapeutics NV (AGMB) stock price registered a noticeable decline on Friday after the stock fell $-0.270 (-2.73%) from the previous session on normal volume. The stock slightly underperformed the market, lagging slightly behind the NASDAQ's 0.31% rise. Yesterday's trading volume was 80 724 shares, worth about $775 758. This represents 55 381 shares less than the day before. Volume was below the 10-day average of 108 220 shares.
AgomAb Therapeutics NV signals
There is no conclusive signals given from RSI. The price is below the short-term average but above the long-term average, with a bullish crossover; this represents a pullback within a broader up-trend. Analysis Impossible: Insufficient signal data is available across all time horizons. A reliable assessment of the directional trend cannot be performed at this time.
AgomAb Therapeutics NV Support & Resistance Levels
The stock is trading above the closest support level at $9.60. approximately $0.01000 (0.10%) away. This suggests it is currently acting as a floor, pushing down towards support.The sup dis das support s19.6 -
AgomAb Therapeutics NV Evaluation
- Short score: -4.08
- Medium score: -4.09
- Long score: -3.62